The story has been updated to correct the market size figure for BioFire Diagnostics' GI and respiratory tests and to correct the previous name of the company.

NEW YORK (GenomeWeb News) – Though it is a relatively new player in the molecular diagnostics space, Salt Lake City-based BioFire Diagnostics sees "tremendous opportunity" for growth during the next 12 to 24 months, its CEO said today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.